| Autor: |
BAI Xin, WU Xinyu, ZHAO Zun, LIU Shuxin, LIU Simiao, XUE Yuhang, XU Junling, GAO Yongju |
| Jazyk: |
čínština |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Zhongguo quanke yixue, Vol 27, Iss 15, Pp 1833-1837 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1007-9572 |
| DOI: |
10.12114/j.issn.1007-9572.2023.0705 |
| Popis: |
Background Differentiated thyroid carcinoma (DTC) with distant metastasis generally forecasts a poor prognosis. Timely diagnosis and effective treatment of distant metastasis are pivotal and challenging in clinical practice. Serum thyroglobulin (Tg) is a marker for monitoring tumor residue or recurrence/metastasis post-surgery and post-131I therapy in DTC. Thyroglobulin antibodies (TgAb) are autoantibodies against Tg that can potentially interfere with Tg measurement. Presently, literature on 131I treatment of TgAb positive DTC with distant metastasis is sparse. Objective To investigate the efficacy of 131I therapy in TgAb positive DTC with distant metastasis. Methods A retrospective analysis was conducted on clinical data of 189 DTC patients treated with 131I from January 2017 to January 2022 at the People's Hospital of Zhengzhou University. Pre-treatment and follow-up measurements of thyroid-stimulating hormone (TSH), Tg, and TgAb were collected. Patients were categorized into TgAb positive (29 cases) and TgAb negative (160 cases) groups. The efficacy of 131I therapy was evaluated. Serum thyroid hormones and routine blood tests were conducted 6-8 weeks post-131I therapy, followed by biannual or annual follow-ups including serum thyroid hormones, Tg, TSH, TgAb, thyroid peroxidase antibodies (TPOAb), neck ultrasound, and CT scans of metastatic sites. Results Statistical significance (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
